KIDNEY TRANSPLANT MARKET ANALYSIS

Kidney Transplant Market Size and Trends

The kidney transplant market is estimated to be valued at USD 9.52 billion in 2024 and is expected to reach USD 12.91 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

To learn more about this report, request sample copy

Kidney Transplant Market Trend

The demand for kidney transplant is expected to increase significantly during the forecast period. This is attributed to the rising prevalence of end-stage renal disease (ESRD) across the world. Additionally, technological advancements in transplant procedures such as laparoscopic and robotic-assisted kidney transplants are gaining popularity among both patients and surgeons. This is owing to benefits such as lesser post-surgery pain, faster recovery time, and fewer complications associated with open surgeries. Moreover, increasing public-private investments to create awareness about organ donation and various transplant programs are further expected to drive the market growth during the forecast period. However, high cost associated with overall transplant procedure and immunosuppressant drugs for lifetime may hinder the growth of this market to some extent.

Increasing Prevalence of Kidney Diseases

The increasing prevalence of various kidney diseases across the globe is a key driver fueling the growth of the kidney transplant market. Kidney diseases have become a major public health problem affecting millions of people worldwide. The rising incidence of chronic conditions such as diabetes and hypertension, coupled with growing geriatric population has significantly contributed to the increasing burden of kidney failure globally. As per statistical estimates, over 2 million people suffer from end-stage kidney disease each year requiring renal replacement therapy in the form of dialysis or kidney transplantation to stay alive. While dialysis offers a lifeline for patients suffering from kidney failure, kidney transplantation is considered the best treatment option as it restores near normal kidney function and improves quality of life. However, shortage of organ donors poses a major challenge. As a result, the number of patients requiring kidney transplantation is growing faster than the availability of donor organs, putting enormous pressure on the global kidney transplant market. For instance, on April 17, 2024, according to data by MJH Life Sciences, the consensus statement emphasizes the global prevalence of kidney disease, surpassing other non-communicable diseases prioritized by the WHO such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. The mortality rates for kidney disease are rising alarmingly, with deaths expected to increase by 100% between 2016 and 2040. According to Mrs.Masaomi Nangaku, president of the International Society of Nephrology, kidney disease currently ranks as the third fastest-growing cause of death worldwide, with deaths increasing by 50% from 2000 to 2019.

Rising Health Expenditure and Improving Access to Care

Another important driver for the kidney transplant market is the overall increase in health expenditure globally. Rising disposable incomes, growing focus on healthcare as a priority, increasing medical insurance penetration, and better access to healthcare facilities have collectively enabled more patients to afford and qualify for expensive procedures such as kidney transplantation. In developed nations, the overall rise in per capita healthcare spending supports ongoing technological advancements and innovations to improve success rates of organ transplantation. At the same time, developing markets which account for the majority of the disease burden are witnessing increased expenditures on complex transplant surgeries. This is primarily attributed to the extensive primary market research over time by governments and private organizations to elevate standards of medical care and make healthcare affordable for greater population. Consequently, more patients worldwide now have access to various stages of kidney transplantation including pre-transplant evaluation, immunosuppressive therapy post transplantation and long-term medical management- ultimately driving higher demand for related services, devices and drugs.

For instance, on May 25, 2024, AstraZeneca's modeling suggests significant cost savings for health systems in four European countries through early CKD screening and treatment. This could prevent numerous heart attacks, heart failure hospitalizations, and strokes. Studies presented at the ERA Congress support the benefits of targeted screening and guideline-directed treatment, showing potential clinical benefits and cost savings. Real-world evidence from the DISCOVER CKD study reinforces the importance of early treatment, while survey data from the PaCE CKD trial highlights the burden of CKD on patients and caregivers. AstraZeneca is advocating for improved CKD policies globally through initiatives like 'Make the Change for Kidney Health.